Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$34.25 USD
+0.75 (2.24%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $34.39 +0.14 (0.41%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Corbus Pharmaceuticals Holdings, Inc. [CRBP]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
An Early-Stage Pipeline with Compelling Scientific Rationale; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Can It Compete? Corbus Expands Its Oncology Footprint With CRB-701, a Nectin-4 Targeting ADC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Corbus Presenting Preclinical Data For CRB-601 During SITC 22; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Integrin áâb8 has Promising Potential in Tumor immunotherapy and Remains a Key Long-term Driver; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Considerations on CRB-601 in Early I/O Pipeline Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
I/O Pipeline Pivot, Creates Questions Before Value; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Turning Page to Integrin Development, Strategic Opportunities; SLE Top-line Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Focusing on Lenabasum Clarity and Evolving Pipeline Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Setback In DM; Focusing Attention on Next Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Diversification Can Further Insulate Pipeline Beyond Lenabasum
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Top-line Data From Lenabasum in DM and SLE at Forefront of Focus; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A